WHO Recommends Antiretroviral Drug Dolutegravir As Preferred HIV Treatment, Including For Women Of Childbearing Age, Pregnant Women

U.N. News: U.N. health agency ‘strongly recommends’ dolutegravir antiretroviral medication to manage HIV
“Based on new evidence, the United Nations health agency on Monday announced it was recommending the use of the antiretroviral drug dolutegravir (DTG) — which, with other medication, treats HIV/AIDS — as the preferred first- and second-line treatment for all cases, including pregnant women and those who have the potential to give birth…” (6/22).

Additional coverage of the new recommendation is available from MedPage Today and The Telegraph.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.